GlassScriptPhysician profile
Vladimir Maletic
NPI 1336217801
$2,581,905.43
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $393K · 2020: $257K · 2021: $343K · 2022: $514K · 2023: $557K · 2024: $517K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $664K · Consulting Fee: $211K · Travel and Lodging: $158K · Honoraria: $23K · Food and Beverage: $16K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $664,303.36 |
| Consulting Fee | $211,355.75 |
| Travel and Lodging | $158,294.25 |
| Honoraria | $23,252.50 |
| Food and Beverage | $16,438.51 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $586,606.22 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $458,365.27 | 2019-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $352,778.88 | 2020-2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $225,882.54 | 2019-2024 | Spravato |
| Allergan, INC. | $214,886.19 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $162,610.52 | 2019-2024 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $130,398.20 | 2023-2024 | Auvelity |
| Sunovion Pharmaceuticals INC. | $114,444.79 | 2019-2022 | |
| Alkermes, INC. | $97,130.65 | 2019-2024 | Lybalvi, Aristada |
| H. Lundbeck A S | $69,155.31 | 2019-2024 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $23,070.34 | 2024 | Cobenfy |
| Janssen Scientific Affairs, LLC | $18,169.37 | 2019-2024 | Spravato |
| Alfasigma USA, INC. | $17,355.00 | 2020-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16,040.00 | 2021-2024 | |
| Eisai INC. | $15,255.70 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $14,596.88 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11,576.61 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $9,743.86 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $9,280.00 | 2023 | |
| Neurelis, INC. | $8,044.52 | 2022 | |
| Janssen Global Services, LLC | $7,532.28 | 2024 | |
| Livanova USA, INC. | $6,151.26 | 2023 | Vns Therapy Symmetry Model 8103 Generator |
| Corium, LLC | $4,577.69 | 2023 | Azstarys |
| Noven Pharmaceuticals, INC. | $4,248.00 | 2021 | |
| Ironshore Pharmaceuticals INC. | $3,685.07 | 2019 | |
| Neurocrine Biosciences, INC. | $320.28 | 2022-2024 | Ingrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vladimir Maletic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.